Boehringer Ingelheim

News

Nine more companies sign pricing deals with Trump

Nine more pharma groups have agreed to lower the costs of medicines in the US under the Trump administration's most favoured nation (MFN) scheme.

News

Measuring tape overlain on a dark yellow background

Pfizer's $2bn+ obesity bet, and other weight-loss news

Pfizer licenses another GLP-1 agonist, from YaoPharma, plus clinical updates from Zealand, Structure, Ascletis, Wave, and Boehringer Ingelheim.

Digital

Interview at Veeva, with BI's Alex Ullrich

Veeva Commercial Summit 2025: On Data harmonisation with Ale...

At Veeva Commercial Summit in Madrid, we spoke with Alexander Ulrich, Global Head of System Integration & Data Ownership at Boehringer Ingelheim.

News

Bayer takes on Boehringer with FDA nod for lung cancer drug

Bayer joins Boehringer with FDA approval for a second-line, oral therapy for HER2-positive lung cancer, setting up a marketing battle in the US.

Oncology

pharmaphorum podcast Episode 211, ESMO25: Boehringer Ingelheim

ESMO25: Patient-centric oncological futures with Boehringer ...

On new oncology data from Boehringer Ingelheim, with Lykke Hinsch Gylvin, chief medical officer, and Itziar Canamasas, head of oncology, at ESMO 2025.

News

Boehringer Ingelheim and Bayer logos with lung sketch in the middle

ESMO: Boehringer, Bayer seek first-line HER2+ NSCLC role

New trial data back the use of Boehringer's new oral HER2 inhibitor Hernexeos in front-line treatment of HER2+ NSCLC, but Bayer is in hot pursuit.

Nine more companies sign pricing deals with Trump

Pfizer's $2bn+ obesity bet, and other weight-loss news

Veeva Commercial Summit 2025: On Data harmonisation with Ale...

Bayer takes on Boehringer with FDA nod for lung cancer drug

ESMO25: Patient-centric oncological futures with Boehringer ...

ESMO: Boehringer, Bayer seek first-line HER2+ NSCLC role

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

Boehringer Ingelheim

Editor's Picks